{"id":34834,"date":"2026-07-13T16:00:00","date_gmt":"2026-07-13T14:00:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=1ac3c1ca47f30b21b2ea8c51cfb73e21"},"modified":"2026-07-13T16:00:00","modified_gmt":"2026-07-13T14:00:00","slug":"chai-discovery-announces-collaboration-with-novartis-to-advance-ai-driven-antibody-discovery","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=34834","title":{"rendered":"Chai Discovery Announces Collaboration with Novartis to Advance AI-Driven Antibody Discovery"},"content":{"rendered":"

\nNovartis will gain access to Chai Discovery\u2019s AI design models and platform to support therapeutic antibody discovery across multiple targets<\/i><\/p><\/a><\/a>

SAN FRANCISCO--(BUSINESS WIRE)--Chai Discovery, the AI company building a computer-aided design suite for molecules, today announced a collaboration with Novartis to advance the discovery of therapeutic antibodies using artificial intelligence.<\/p>

\nUnder the collaboration, Novartis will gain access to Chai\u2019s latest AI models, including the Chai-3 model, to support Novartis in the discovery of antibodies for therapeutic programs across multiple targets.<\/p>

\nThe agreement builds on more than a year of technical engagement between the two companies, including early access to Chai\u2019s next-generation folding model last spring. After tracking Chai\u2019s progress in AI-driven molecular design over the past year, Novartis and Chai are now extending their work together to support broader deployment across multiple therapeutic programs.<\/p>

\nChai Discovery uses AI to predict and reprogram molecular interactions, helping scientists design new biomolecules with specific properties. Chai\u2019s AI models are designed to accelerate drug discovery by generating molecules based on defined criteria and compressing discovery cycles.<\/p>

\n\u201cWe are delighted to be collaborating with Novartis in the discovery of new antibodies,\u201d said Joshua Meier, co-founder and CEO of Chai Discovery<\/b>. \u201cThis is a significant step forward in expanding the range of therapeutic programs that can benefit from AI-driven molecular design.\u201d<\/p>

\n\u201cAI is already reshaping how we discover medicines,\u201d said Fiona Marshall, President of Biomedical Research at Novartis<\/b>. \u201cBy applying advanced models to challenges like antibody design, we can explore a broader range of possibilities, make better decisions earlier, and focus our efforts on the most promising candidates. Our collaboration with Chai Discovery brings complementary expertise to tackle difficult targets and advance progress toward new options for patients.\u201d<\/p>

\nChai Discovery\u2019s collaboration with Novartis follows previously announced customer agreements with Pfizer and Eli Lilly. Financial terms of the agreement with Novartis are not being disclosed.<\/p>

\nAbout Chai Discovery<\/b><\/p>

\nChai Discovery is building a world where new medicines are not found through trial and error, but designed with the precision, speed and scale of modern engineering. Chai\u2019s models are designed to reason about biological structure and function, generate new molecular designs from scratch, and help pharma teams pursue targets that traditional discovery methods have struggled to reach.<\/p>

\nFounded in 2024 by Joshua Meier, Jack Dent, Matthew McPartlon and Jacques Boitreaud, Chai Discovery is based in San Francisco, California. With backgrounds spanning OpenAI, Meta FAIR, Stripe, molecular design and academic research, the team shares a singular vision: to bring the precision and predictability of engineering to one of the hardest problems in science - better, faster therapeutics, for even the toughest 'undruggable' conditions.<\/p>

\nChai Discovery is backed by top investors, including Oak HC\/FT, General Catalyst, OpenAI, Thrive Capital, Menlo Ventures and Dimension.<\/p> Contacts<\/b>

\npress@chaidiscovery.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"

Novartis will gain access to Chai Discovery\u2019s AI design models and platform to support therapeutic antibody discovery across multiple targetsSAN FRANCISCO–(BUSINESS WIRE)–Chai Discovery, the AI company building a computer-aided design suite for mole…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-34834","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/34834","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=34834"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/34834\/revisions"}],"predecessor-version":[{"id":34835,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/34834\/revisions\/34835"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=34834"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=34834"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=34834"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}